FDA Orders New Eye-Risk Warnings for Ozempic, Wegovy, Mounjaro and Zepbound
The U.S. Food and Drug Administration is requiring every glucagon-like peptide-1 receptor agonist, or GLP-1 medicine, to carry new warnings about a potential increased risk of a rare but serious eye condition that can cause sudden and sometimes permanent vision loss.
The labeling change announced Monday, November 9, applies across the fast-growing drug class, including Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Victoza and Saxenda. These medicines are used to treat type 2 diabetes, obesity and related health risks.
What the FDA announced
The agency said manufacturers must add information about non-arteritic anterior ischemic optic neuropathy, known as NAION, to the “Warnings and Precautions” section of prescribing information and to patient medication guides. The FDA described the evidence as showing a potential increased risk—not proof that GLP-1 drugs directly cause the condition.
NAION happens when blood flow to the optic nerve is reduced or blocked. The optic nerve carries visual information from the eye to the brain. Damage can produce sudden, painless loss of vision, usually in one eye, and the loss may be permanent.
Symptoms that need immediate attention
The FDA advised patients taking a GLP-1 medicine to contact a health professional immediately if they experience sudden or worsening vision changes. Warning signs can include a painless decrease in vision in one eye, new blind spots or tunnel vision, distorted color perception, or loss of sharp central vision.
Patients should not stop a prescribed medicine on their own solely because of the announcement. Abruptly ending diabetes or weight-management treatment can have consequences. Anyone concerned about the warning should discuss individual benefits and risks with the clinician who prescribed the drug.
How large is the risk?
The condition remains rare. In an FDA analysis of 126 randomized controlled trials involving 134,253 patients, NAION occurred at a rate of 6.4 cases per 100,000 person-years among people receiving a GLP-1 drug, compared with 3.8 cases per 100,000 person-years among patients receiving a comparator treatment.
A separate study using the FDA’s Sentinel healthcare-data system produced mixed results. Compared with SGLT-2 diabetes medicines, the analysis did not find a statistically significant increase in risk. Compared with DPP-4 inhibitors, however, it found a statistically significant association. The FDA said the total evidence supports adding a warning while emphasizing that a biological mechanism has not been identified and causation has not been established.
Which medicines are covered?
The new labeling requirement covers all GLP-1 receptor agonists, not only the best-known weight-loss brands. It includes semaglutide products such as Ozempic, Wegovy and Rybelsus; tirzepatide products Mounjaro and Zepbound; dulaglutide sold as Trulicity; and liraglutide products Victoza and Saxenda, among others.
Some of these medicines are approved for diabetes, some for chronic weight management, and some for reducing cardiovascular or other health risks in particular patients. Their indications and doses differ, so the FDA’s class-wide action does not mean every patient faces the same risk.
What doctors are being told
Health professionals should tell patients about the symptoms of NAION and refer anyone with sudden vision changes for prompt ophthalmic evaluation. If NAION is diagnosed, the FDA says clinicians should discuss whether to discontinue the GLP-1 medicine, unless the expected benefit of continuing treatment outweighs the potential risk for that patient.
The agency also asked clinicians and patients to report suspected adverse events through the FDA’s MedWatch program. Such reports can help regulators monitor a rare safety signal after widely used drugs reach large populations.
Drugmakers respond
Eli Lilly, which makes Mounjaro and Zepbound, said it is evaluating the FDA’s announcement. Novo Nordisk, the maker of Ozempic, Wegovy and Rybelsus, said available evidence does not establish a causal relationship and that it continues to consider the medicines’ benefit-risk profiles favorable. The European Medicines Agency previously added NAION as a very rare semaglutide side effect.
The bottom line
The new warning is important because GLP-1 medicines are used by millions of people, but the FDA’s figures indicate that NAION is still uncommon. The practical message is not to panic or quit treatment without medical advice. Instead, patients should know the symptoms, treat sudden painless vision loss as urgent and speak with their healthcare professional about their personal risk.
Sources
- U.S. Food and Drug Administration: Drug Safety Communication, November 9, 2026
- FDA MedWatch Safety Alert, November 9, 2026
- Reuters: FDA orders new eye-risk warnings for GLP-1 drugs, November 9, 2026
